scholarly journals Construção de material educativo para pacientes e acompanhantes de um serviço de radioterapia

2021 ◽  
Vol 11 (34) ◽  
pp. 212-219
Author(s):  
Francisco Leandro da Silva Brito ◽  
Ana Carolina de Oliveira Rocha
Keyword(s):  
Adverse Effects ◽  
Technology Development ◽  
Educational Material ◽  
Treatment Modalities ◽  
Oncology Nursing ◽  
Methodological Study ◽  
Health Technologies ◽  
Therapeutic Modalities ◽  
Reference Hospital ◽  
The City

A radioterapia é uma das modalidades de tratamento oncológico e pode ser usada como tratamento principal e em conjunto com outras modalidades terapêuticas. Por esse motivo, acarreta diversas compilações/efeitos adversos. Este trabalho objetivou a construção de um folder, para os usuários (pacientes e acompanhantes) que utilizam o serviço de radioterapia de um hospital referência em oncologia na cidade de Fortaleza, Ceará. Para construção do folder, foi realizado um estudo metodológico, do tipo desenvolvimento de tecnologia, obedecendo 3 etapas: sistematização do conteúdo, escolha das ilustrações, composição do conteúdo. Como resultado, foi desenvolvido o folder intitulado “Guia de Orientações para Pacientes e Acompanhantes: radioterapia SUS”. O trabalho de conscientização e educação em saúde através do uso de tecnologias em saúde como o folder, possibilita o aumento do conhecimento dos pacientes, tornando-os capazes de refletir, gerando mudanças de percepções e atitudes diferentes nos cuidados com a saúde.Descritores: Enfermagem Oncológica, Radioterapia, Oncologia, Educação em Saúde. Construction of educational material for patients and companions of a radiotherapy serviceAbstract: Radiotherapy is one of the cancer treatment modalities and can be used as the main treatment and in conjunction with other therapeutic modalities. For this reason, it causes several compilations/adverse effects. This work aimed to build a folder for users (patients and companions) who use the radiotherapy service of a reference hospital in oncology in the city of Fortaleza, Ceará. For the construction of the folder, a methodological study was carried out, of the type of technology development, following 3 stages: the systematization of the content, choice of illustrations, the composition of the content. As a result, the folder entitled “Guide for Orientations for Patients and Companions: SUS radiotherapy” was developed. The work of health awareness and education through the use of health technologies such as the folder makes it possible to increase the knowledge of patients, making them able to reflect, generating changes in perceptions and different attitudes in health care.Descriptors: Oncology Nursing, Radiotherapy, Oncology, Health Education. Construcción de material educativo para pacientes y acompañantes de un servicio de radioterapiaResumen: La radioterapia es una de las modalidades de tratamiento del cáncer y se puede utilizar como tratamiento principal y junto con otras modalidades terapéuticas. Por esta razón, provoca varias recopilaciones / efectos adversos. Este trabajo tuvo como objetivo la construcción de un folleto carpeta para los usuarios (pacientes y acompañantes) que utilizan el servicio de radioterapia de un hospital de referencia en oncología de la ciudad de Fortaleza, Ceará. Para la construcción de la carpeta se realizó un estudio metodológico, del tipo de desarrollo tecnológico, siguiendo 3 etapas: sistematización del contenido, elección de ilustraciones, composición del contenido. Como resultado, se desarrolló la carpeta titulada “Guía de Orientaciones para Pacientes y Acompañantes: radioterapia SUS”. La labor de sensibilización y educación en salud a través del uso de tecnologías de la salud como la carpeta, permite incrementar el conocimiento de los pacientes, haciéndolos capaces de reflexionar, generando cambios en las percepciones y diferentes actitudes en el cuidado de la salud.Descriptores: Enfermería Oncológica, Radioterapia, Oncología, Educación para la Salud.

scholarly journals MiRNA10b-directed nanotherapy effectively targets brain metastases from breast cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Byunghee Yoo ◽  
Alana Ross ◽  
Pamela Pantazopoulos ◽  
Zdravka Medarova
Keyword(s):  
Breast Cancer ◽  
Rna Interference ◽  
Lymph Nodes ◽  
Therapeutic Effect ◽  
Metastatic Breast ◽  
Treatment Modalities ◽  
Transcriptional Level ◽  
Metastatic Progression ◽  
Therapeutic Modalities ◽  
Metastatic Colonization

AbstractRNA interference represents one of the most appealing therapeutic modalities for cancer because of its potency, versatility, and modularity. Because the mechanism is catalytic and affects the expression of disease-causing antigens at the post-transcriptional level, only small amounts of therapeutic need to be delivered to the target in order to exert a robust therapeutic effect. RNA interference is also advantageous over other treatment modalities, such as monoclonal antibodies or small molecules, because it has a much broader array of druggable targets. Finally, the complementarity of the genetic code gives us the opportunity to design RNAi therapeutics using computational, rational approaches. Previously, we developed and tested an RNAi-targeted therapeutic, termed MN-anti-miR10b, which was designed to inhibit the critical driver of metastasis and metastatic colonization, miRNA-10b. We showed in animal models of metastatic breast cancer that MN-anti-miR10b accumulated into tumors and metastases in the lymph nodes, lungs, and bone, following simple intravenous injection. We also found that treatment incorporating MN-anti-miR10b was effective at inhibiting the emergence of metastases and could regress already established metastases in the lymph nodes, lungs, and bone. In the present study, we extend the application of MN-anti-miR10b to a model of breast cancer metastatic to the brain. We demonstrate delivery to the metastatic lesions and obtain evidence of a therapeutic effect manifested as inhibition of metastatic progression. This investigation represents an additional step towards translating similar RNAi-targeted therapeutics for the systemic treatment of metastatic disease.

scholarly journals Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Chen Li ◽  
Yan Wang ◽  
Yueqing Gong ◽  
Tengrui Zhang ◽  
Jiaqi Huang ◽  
...  
Keyword(s):  
Treatment Modalities ◽  
Preclinical Studies ◽  
Combination Therapies ◽  
Tumor Treatment ◽  
Antitumor Effects ◽  
Therapeutic Modalities ◽  
Combination Strategies ◽  
Anti Cancer ◽  
Underlying Mechanisms ◽  
The Individual

AbstractEnhancer of zeste homolog 2 inhibitors (EZH2i) have garnered increased attention owing to their anticancer activity by targeting EZH2, a well-known cancer-promoting factor. However, some lymphomas are resistant to EZH2i, and EZH2i treatment alone is ineffective in case of EZH2-overexpressing solid tumors. The anti-cancer efficacy of EZH2i may be improved through safe and effective combinations of these drugs with other treatment modalities. Preclinical evidence indicates that combining EZH2i with other therapies, such as immunotherapy, chemotherapy, targeted therapy, and endocrine therapy, has complementary or synergistic antitumor effects. Therefore, elucidating the underlying mechanisms of the individual constituents of the combination therapies is fundamental for their clinical application. In this review, we have summarized notable clinical trials and preclinical studies using EZH2i, their progress, and combinations of EZH2i with different therapeutic modalities, aiming to provide new insights for tumor treatment.

scholarly journals Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects

2021 ◽  
Vol 28 (1) ◽  
pp. 640-660
Author(s):  
Grace Lassiter ◽  
Cole Bergeron ◽  
Ryan Guedry ◽  
Julia Cucarola ◽  
Adam M. Kaye ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cells ◽  
Hematologic Malignancy ◽  
Drug Efficacy ◽  
Treatment Modalities ◽  
Blurred Vision ◽  
Refractory Multiple Myeloma ◽  
Therapeutic Modalities ◽  
Clonal Proliferation ◽  
Refractory State

Multiple myeloma (MM) is a hematologic malignancy characterized by excessive clonal proliferation of plasma cells. The treatment of multiple myeloma presents a variety of unique challenges due to the complex molecular pathophysiology and incurable status of the disease at this time. Given that MM is the second most common blood cancer with a characteristic and unavoidable relapse/refractory state during the course of the disease, the development of new therapeutic modalities is crucial. Belantamab mafodotin (belamaf, GSK2857916) is a first-in-class therapeutic, indicated for patients who have previously attempted four other treatments, including an anti-CD38 monoclonal antibody, a proteosome inhibitor, and an immunomodulatory agent. In November 2017, the FDA designated belamaf as a breakthrough therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. In August 2020, the FDA granted accelerated approval as a monotherapy for relapsed or treatment-refractory multiple myeloma. The drug was also approved in the EU for this indication in late August 2020. Of note, belamaf is associated with the following adverse events: decreased platelets, corneal disease, decreased or blurred vision, anemia, infusion-related reactions, pyrexia, and fetal risk, among others. Further studies are necessary to evaluate efficacy in comparison to other standard treatment modalities and as future drugs in this class are developed.

scholarly journals Suicide attempts by exogenous intoxication among female adolescents treated at a reference hospital in the city of Recife-PE, Brazil

2011 ◽  
Vol 64 (5) ◽  
pp. 833-838 ◽  
Author(s):  
Juliana Lourenço de Araújo Veras ◽  
Cintia Regina Tornisiello Katz
Keyword(s):  
Suicide Attempts ◽  
Family Relations ◽  
Care Center ◽  
Female Adolescents ◽  
Treatment Programs ◽  
Structured Interviews ◽  
Vulnerable Group ◽  
Toxic Agent ◽  
Reference Hospital ◽  
The City

This study aimed to assess cases of self-inflicted poisoning among adolescents reported by the Toxicological Care Center of a reference hospital in Recife-PE, Brazil. The data were collected between March and May 2010 from hospital charts and structured interviews with the participants and parents/guardians. Among the 25 cases of attempted suicide registered in the period, 21 were female adolescents, who made up the sample of the present study. The adolescents were between 13 and 19 years of age. Pesticides were the most frequent toxic agent used (61.9%). The results of the present study underscore the importance of studying suicide in this population, with a focus on family relations, in order to lay the foundation for the development of prevention and treatment programs for this vulnerable group.

Special Considerations in the Use of Glucocorticoids in Children

1995 ◽  
Vol 16 (7) ◽  
pp. 266-272
Author(s):  
Joseph D. Spahn ◽  
Alan K. Kamada
Keyword(s):  
Adverse Effects ◽  
Autoimmune Diseases ◽  
Early Recognition ◽  
Therapeutic Effects ◽  
Therapeutic Modalities ◽  
High Doses

GCs are used commonly for the treatment of various inflammatory and autoimmune diseases. Although potent and generally effective, they are not without risks for producing serious adverse effects, especially when used in high doses for prolonged periods of time. Thus, the clinician must balance the therapeutic effects of GCs with their risks for adverse effects; using the lowest possible effective GC doses as well as maximizing other therapeutic modalities are means by which this goal can be achieved. Early recognition and appropriate management are other methods to minimize GC-induced adverse effects. Maximization of therapy, early recognition, and appropriate management of adverse effects can minimize the potential severe complications of GC therapy.

scholarly journals Analysis of response of vitiligo to treatment with NBUVB

2019 ◽  
Vol 5 (1) ◽  
pp. 37
Author(s):  
J. Madhava Praveen ◽  
Jatin Sidhwa
Keyword(s):  
Adverse Effects ◽  
Skin Disorder ◽  
Environmental Risks ◽  
Treatment Modalities ◽  
Duration Of Treatment ◽  
Autoimmune Attack ◽  
Self Worth ◽  
Good Treatment Response ◽  
Dynamic Interplay

<p class="abstract"><strong>Background:</strong> Vitiligo is an acquired skin disorder characterised by white (depigmented) patches in the skin, due to the loss of functioning melanocytes. The disease can have devastating consequences on an individual’s relationships with others and internal feelings of self-worth. Vitiligo is caused by a dynamic interplay between genetic and environmental risks that initiates an autoimmune attack on melanocytes in the skin. Long term phototherapy has shown good response in the management of vitiligo. In this study we explore the efficacy of phototherapy in management of our vitiligo patients.</p><p class="abstract"><strong>Methods:</strong> 30 subjects were included in the study. Subjects were started on NBUVB at 300mj/cm<sup>2</sup>. Weekly 3 doses were given. Doses were increased after every 3<sup>rd</sup> sitting by 10%. In case of adverse effects treatment is withheld till resolution of symptoms following which NBUVB is given at 50% of the last dose and patient managed based on the response.<strong></strong></p><p class="abstract"><strong>Results:</strong> A majority of the subjects showed significant and persistent improvement within the first 3 months of initiation of treatment. The proportion of the patients showing improvement increased with duration of treatment.</p><p class="abstract"><strong>Conclusions:</strong> Our study has revealed the standard and significant role the phototherapy plays in the treatment of vitiligo as a monotherapy or as an adjuvant with other treatment modalities. With good treatment response and minimal side effect incidence, phototherapy is an important treatment modality in the management of vitiligo.</p><p> </p>

scholarly journals Modeling in Early Stages of Technology Development: Is an Iterative Approach Needed? Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling"

2019 ◽  
Author(s):  
Michael F. Drummond
Keyword(s):  
Health Economic ◽  
Technology Development ◽  
Integrated Approach ◽  
Economic Modeling ◽  
Future Research ◽  
Iterative Approach ◽  
Health Technologies ◽  
Early Health ◽  
The Cost

A recent paper by Grutters et al makes the case for early health economic modeling in the development of health technologies. A number of examples of the value of early modeling are given, with analyses being performed at different stages in the development of several non-drug health technologies. This commentary acknowledges the contribution of the paper by Grutters et al and argues for an iterative and integrated approach to early modeling, assessing the cost-effectiveness of the technology, the value of future research and the interaction with the manufacturer’s pricing and revenue expectations.

Health Technology Assessment

2011 ◽  
pp. 26-41
Author(s):  
Lise Lund Haheim ◽  
Berit Morland
Keyword(s):  
Information Flow ◽  
Health Professionals ◽  
Rapid Development ◽  
New Drugs ◽  
Treatment Modalities ◽  
Industrialized Countries ◽  
Scientific Publications ◽  
The Public ◽  
Health Technologies ◽  
Health Authorities

Scientific publications in medical fields are rapidly increasing and are overwhelming in numbers. This poses a challenge to health authorities, and health professionals who need knowledge to make informed decisions in finding the best evidence for treatment and practice in the health provision to the public. They need an accessible system that handle the information flow using a systematic approach. This applies to developing and industrialized countries alike. The rapid development of health technologies with the introduction of new drugs, devices, and complex treatment modalities to achieve better health outcomes increases the need for evaluation of the treatment effect. This chapter illustrates how the health service handles the information flow utilizing information technology, and the great benefit that is gained by this methodology.

scholarly journals P86 Treatment modalities in peripheral facial nerve palsy in children and adolescents

2019 ◽  
Vol 104 (6) ◽  
pp. e53.1-e53
Author(s):  
J Samardzic ◽  
B Kukolj ◽  
M Jovanovic ◽  
O Djuric ◽  
J Jancic
Keyword(s):  
Recovery Rate ◽  
Combined Therapy ◽  
Recovery Period ◽  
Treatment Modalities ◽  
P Value ◽  
Physical Treatment ◽  
Therapeutic Modalities ◽  
Peripheral Facial Palsy ◽  
Younger Age ◽  
Peripheral Facial Nerve Palsy

BackgroundBell´s palsy is the most common type of peripheral facial palsy in pediatrics. Recent studies strongly support the combined therapy with corticosteroids (CS), antiviral drugs and vitamins B. Our study aims to assess the effectiveness of proposed therapeutic modalities, including the relation between the patients‘ recovery and their age, etiological factors and applied treatment.MethodsThe retrospective analysis involved 88 patients (52 females/36 males), between 18 months and 18 years old; the average age was 11.7 years. Data was obtained from the documentation of patients hospitalized at the Clinic of Neurology and Psychiatry for Children and Youth in Belgrade, from 2000 to 2017. House Brackmann´s scale was used for the assessment of disease course and outcome. Pearson´s χ2 test, Friedman´s test and general linear model were applied for statistical data processing.ResultsThe majority of patients were treated with combined CS/vitamins (42.0%) and CS/antiviral/vitamins (17.0%), whereas CS only received 22.7% of patients, all with an appropriate physical treatment. The group of idiopathic paralysis makes 62.5%, while the incidence of symptomatic paralysis is 37.5%; however, the recovery rate between these groups has not been shown (p=0.309). Patients received CS therapy were divided into 4 groups: CS only, CS+antiviral, CS+vitamins B, and CS+antiviral+vitamins B. The statistically significant recovery was registered in each group (p< 0.001); however, no difference was found between the groups in term of recovery rate (p=865). For the assessment of recovery period in relation to the age, the obtained p value was 0.054, a borderline level, suggesting a faster recovery of children at younger age.ConclusionThe acute one-sided mimic musculature weakness is mostly idiopathic. The effectiveness of the CS therapy was strongly supported, suggesting CS as a core treatment for the Bell´s palsy. It has been shown the faster recovery of children at younger age.Disclosure(s)Nothing to disclose

scholarly journals Development of Immunopathogenesis Strategies to Treat Behçet’s Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Osman Köse
Keyword(s):  
Molecular Structure ◽  
Biologic Agents ◽  
Treatment Modalities ◽  
The Novel ◽  
Therapeutic Modalities ◽  
Novel Treatment ◽  
Unclear Etiology ◽  
Antigen Presenting ◽  
Disease Understanding ◽  
Novel Therapeutic

Behçet disease is a chronic relapsing vasculitis with unclear etiology and immunopathogenesis. Antigenic stimuli, antigen presenting cells, T cells, monocyte, and neutrophil and endothelial cells are major parts of the pathology of the disease. Understanding of the new pathogenic mechanisms based on molecular structure of the disease helps us in improving the novel therapeutic modalities. These drugs target specific and nonspecific inhibition of the immun system. These therapies include biologic agents, new topical and systemic immunosuppressants, tolerizing agents, and immunoablation. Novel treatment will be promising to treat the especially recalcitrant cases to conventional therapy. In this paper, new aspect of the immunopathogenesis of Behçet’s diseases and novel treatment modalities will be discussed.

Sign in / Sign up

Export Citation Format

Share Document